Correspondence
Published: 26 July 2024
Nature Biotechnology
(2024)Cite this article
Response to anticancer treatment is dictated not only by availability of molecular targets within the tumor, but also by the highly heterogenous, patient-specific composition of cells within tumors and their complex tumor microenvironment (TME). Consequently, some patients demonstrate remarkable responses to anticancer therapies, whereas others experience negligible effects. Thus, there is an urgent need for more effective strategies to preselect patients for therapies, mitigating the risk of administering ineffective and potentially harmful drugs and speeding up the process for patients to receive the most effective treatment.
The most promising solution to tackle heterogenous responses to treatment is the creation of patient-derived models (‘patient avatars’) that accurately represent an individual’s tumor. Tailoring therapies for cancer patients based on their avatars’ responses to anticancer drugs could change the entire approach to treating patients with solid tumor diseases. Although introducing these human in vitro systems into clinical settings has been challenging, recent evidence has demonstrated the readiness of these models for clinical translation.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
24,99 € / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
209,00 € per year
only 17,42 € per issue
Buy this article
Purchase on Springer LinkInstant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Log in
Learn about institutional subscriptions
Read our FAQs
Contact customer support
References
Vlachogiannis, G. et al. Science359, 920–926 (2018).
Tan, T. et al. Cell Rep. Med.4, 101335 (2023).
Dekkers, J. F. et al. Nat. Biotechnol.41, 60–69 (2023).
Dijkstra, K. K. et al. Cell174, 1586–1598.e12 (2018).
Harter, M. F. et al. Nat. Biomed. Eng.8, 345–360 (2023).
Neal, J. T. et al. Cell175, 1972–1988.e16 (2018).
Gavert, N. et al. Nat. Cancer3, 219–231 (2022).
Kaptein, P. et al. Sci. Transl. Med.14, eabj9779 (2022).
Voabil, P. et al. Nat. Med.27, 1250–1261 (2021).
Lorenzo-Martín, L. F. et al. Nature629, 450–457 (2024).
Kong, J. et al. Nat. Commun.11, 5485 (2020).
Neufeld, L. et al. Sci. Adv.7, eabi9119 (2021).
Download references
Author information
Authors and Affiliations
Berlin Institute of Health (BIH) at Charité — Universitätsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Experimental Immunotherapy, Berlin, Germany
Lukas Ehlen & Michael Schmueck-Henneresse
Department of Anesthesiology and Intensive Care Medicine, Charité – Universitätsmedizin Berlin, Berlin, Germany
Lukas Ehlen
Contributions
L.E. and M.S.-H. wrote the manuscript. Both authors have read and approved the manuscript in its final form.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
About this article
Cite this article
Ehlen, L., Schmueck-Henneresse, M. The rise of patient avatars in precision oncology.
Nat Biotechnol (2024). https://doi.org/10.1038/s41587-024-02335-8
Download citation
Published: 26 July 2024
DOI: https://doi.org/10.1038/s41587-024-02335-8
>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : Nature.com – https://www.nature.com/articles/s41587-024-02335-8